Castle Biosciences Inc.
Castle Biosciences, Inc., a commercial-stage dermatological cancer company, focuses to provide diagnostic and prognostic solutions for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify high-risk patients with stage I and II melanomas based on biological information from 31 genes within their tumor tissue. The company also offers DecisionDx-UM test, a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma, a rare eye cancer; DecisionDx-SCC, a proprietary 40-gene expression profile test that uses an individual patient's tumor biology to predict individual risk of squamous cell carcinoma metastasis for patients with one or more risk factors; and DecisionDx DiffDx-Melanoma, a proprietary GEP test for suspicious pigmented lesions. It offers test services through physicians and their patients. The company was founded in 2007 and is headquartered in Friendswood, Texas.
IPO Year: 2019
Exchange: NASDAQ
Website: castlebiosciences.com
Recent Analyst Ratings for Castle Biosciences Inc.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/14/2023 | $25.00 | Buy | Guggenheim |
| 1/5/2023 | $54.00 | Sector Outperform | Scotiabank |
| 1/7/2022 | $59.00 | Overweight | Stephens & Co. |
| 11/9/2021 | $85.00 → $75.00 | Outperform | SVB Leerink |
| 7/14/2021 | $80.00 → $85.00 | Outperform | SVB Leerink |
Castle Biosciences Inc. Press Releases
Fastest customizable press release news feed in the world
Castle Biosciences' DecisionDx®-SCC Data Earns Top Five Abstract at NCCN 2025, Shows Significantly Enhanced Risk Stratification Beyond Current Staging Within NCCN Risk Groups
New, combined validation cohort of 1,412 patients with high-risk squamous cell carcinoma (SCC) demonstrates that the addition of DecisionDx-SCC to Brigham & Women's Hospital (BWH) staging significantly refines metastatic risk prediction in patients classified as High-Risk and Very High-Risk by National Comprehensive Cancer Network (NCCN) guidelines to support improved, risk-aligned treatment pathway decisions Castle will also present new data showing DecisionDx®-Melanoma as a significant predictor of mortality in a real-world cohort of nearly 7,000 patients with early-stage cutaneous melanoma (CM), reinforcing its value in identifying patients who may benefit from treatment plan strategies
New Data to be Presented at the 2025 American Academy of Dermatology (AAD) Annual Meeting Further Strengthens Evidence Supporting the Clinical Value of Castle Biosciences' Dermatology Portfolio
New study corroborates DecisionDx®-SCC's ability to independently predict metastatic risk in patients with high-risk cutaneous squamous cell carcinoma (SCC) Landmark analysis of nearly 10,000 patients through Castle's collaboration with the National Cancer Institute's Surveillance, Epidemiology and End Results (SEER) Program Registries showed a significant association between DecisionDx®-Melanoma testing and improved survival in melanoma patients Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, will share new data on its DecisionDx-Melanoma and DecisionDx-SCC tests for patients with skin cancers at the 2025 AAD Annual Mee
Castle Biosciences Reports Fourth Quarter and Full-Year 2024 Results
Full-year 2024 revenue of $332 million, an increase of 51% compared to 2023 and above previously reported guidance Delivered 96,071 total test reports in 2024, an increase of 36% compared to 2023 Year-end 2024 cash, cash equivalents and marketable investment securities of $293 million, a $50 million increase compared to 2023 Anticipate generating between $280-295 million in total revenue in 2025 Conference call and webcast today at 4:30 p.m. ET Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced its financial results for the fourth quarter and year ended December 31, 2024. "Castle delivered an outst
Castle Biosciences to Participate in Upcoming Investor Conferences
Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced that its executive management is scheduled to present a company overview at the following investor conferences next month: Leerink Partners Global Healthcare Conference on March 10, 2025, at 1:40 p.m. Eastern time. KeyBanc Capital Markets Healthcare Forum, occurring virtually on March 18, 2025, at 11:15 a.m. Eastern time. Live audio webcasts of the Company's presentations will be available by visiting Castle Biosciences' website at https://ir.castlebiosciences.com/events-presentations/default.aspx. Replays of the webcasts will be available following t
Castle Biosciences to Share Data Reinforcing the Clinical Value of Its Dermatologic Portfolio of Gene Expression Profile Tests at the 22nd Annual Winter Clinical Dermatology Conference - Hawaii®
Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, will share data supporting its dermatologic portfolio of gene expression profile (GEP) tests at the 2025 Winter Clinical Dermatology Conference - Hawaii, taking place Feb. 14-19 in Waikoloa Village, Hawaii. "As long-standing supporters of the Winter Clinical Dermatology Conferences, we aim to facilitate meaningful conversations on advancing patient care," said Rebecca Critchley-Thorne, Ph.D., vice president of research and development at Castle Biosciences. "The data we are sharing reinforces our commitment to improving the care of patients with skin cancers through innovat
Castle Biosciences to Release Fourth Quarter and Full-Year 2024 Financial Results and Host Conference Call on Thursday, Feb. 27, 2025
Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced that it will release its financial results for the fourth quarter and year ended Dec. 31, 2024, after the close of market on Thursday, Feb. 27, 2025. Company management will host a conference call and webcast to discuss its financial results at 4:30 p.m. Eastern time on the same day. Conference Call and Webcast Details A live webcast of the conference call can be accessed here: https://events.q4inc.com/attendee/686536610, or via the webcast link on the Investor Relations page of the Company's website: https://ir.castlebiosciences.com/overview/default.asp
Castle's Poster on DecisionDx®-SCC Selected as a "Late Breakers" Top Five Finalist for the Akamai Award, Recognizing the Best Posters at Maui Derm Hawaii 2025
Highlights from Castle's DecisionDx-SCC poster will be shared in a special podium presentation during the Late Breakers 2025 session on Tuesday, Jan. 21, from 10:45-11:15 a.m. local time Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, will share data supporting its dermatologic portfolio of tests for skin cancer, DecisionDx-SCC, DecisionDx®-Melanoma and MyPath® Melanoma, through poster presentations at the annual Maui Derm Hawaii meeting, being held Jan. 20-24, 2025, in Maui, Hawaii. The Company's poster on DecisionDx-SCC, which was selected as a "Late Breakers" top five finalist for the best poster Akamai Award, share
Castle Biosciences Announces Preliminary Unaudited Fourth Quarter and Full-Year 2024 Results
2024 total revenue expected to meet or exceed top end of guided range of $320-330 million, at least 50% growth over 2023 Delivered 96,071 total test reports in 2024, an increase of 36% compared to 2023 Year-end 2024 cash, cash equivalents and marketable investment securities expected to be approximately $293 million Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced certain unaudited preliminary performance results for the fourth quarter and year ended Dec. 31, 2024. "Our strong fourth quarter performance underscores continued momentum built throughout 2024, reflecting the strength of our growth initia
Castle Biosciences Announces New York State Department of Health Approval of Its TissueCypher® Barrett's Esophagus Test
With this approval, all of the tests in Castle's dermatology, gastroenterology and ophthalmology portfolios, as well as its clinical laboratories in Phoenix and Pittsburgh, are now approved by the state of New York Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced that it has received assay approval from the New York State Department of Health (NYSDOH) for its TissueCypher Barrett's Esophagus test. TissueCypher is the first AI-driven precision medicine test designed to predict a patient's individual risk of progression from Barrett's esophagus (BE) to esophageal cancer. "We are proud of the expansion of o
Castle Biosciences Highlights Progress for its Pipeline Atopic Dermatitis Gene Expression Profile Test
Assuming successful validation, the Company currently expects to launch the pipeline test by the end of 2025 Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today provided an update on its test currently in development for use in patients diagnosed with moderate-to-severe atopic dermatitis (AD) who are seeking systemic treatment. Based on preliminary data from the Company's ongoing prospective development and validation study, Castle's pipeline test has shown potential to identify a subset of patients with AD who have an increased likelihood to achieve a super response to targeted therapies, indicated by a 90% or greater
Castle Biosciences Inc. Analyst Ratings
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
Guggenheim initiated coverage on Castle Biosciences with a new price target
Guggenheim initiated coverage of Castle Biosciences with a rating of Buy and set a new price target of $25.00
Scotiabank initiated coverage on Castle Biosciences with a new price target
Scotiabank initiated coverage of Castle Biosciences with a rating of Sector Outperform and set a new price target of $54.00
Stephens & Co. initiated coverage on Castle Biosciences with a new price target
Stephens & Co. initiated coverage of Castle Biosciences with a rating of Overweight and set a new price target of $59.00
SVB Leerink reiterated coverage on Castle Biosciences with a new price target
SVB Leerink reiterated coverage of Castle Biosciences with a rating of Outperform and set a new price target of $75.00 from $85.00 previously
SVB Leerink reiterated coverage on Castle Biosciences with a new price target
SVB Leerink reiterated coverage of Castle Biosciences with a rating of Outperform and set a new price target of $85.00 from $80.00 previously
Lake Street initiated coverage on Castle Biosciences with a new price target
Lake Street initiated coverage of Castle Biosciences with a rating of Buy and set a new price target of $94.00
Robert W. Baird reiterated coverage on Castle Biosciences with a new price target
Robert W. Baird reiterated coverage of Castle Biosciences with a rating of Outperform and set a new price target of $82.00 from $87.00 previously
KeyBanc reiterated coverage on Castle Biosciences with a new price target
KeyBanc reiterated coverage of Castle Biosciences with a rating of Overweight and set a new price target of $90.00 from $70.00 previously
Canaccord Genuity reiterated coverage on Castle Biosciences with a new price target
Canaccord Genuity reiterated coverage of Castle Biosciences with a rating of Buy and set a new price target of $84.00 from $80.00 previously
Castle Biosciences Inc. Insider Trading
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
Pres. & Chief Exec. Officer Maetzold Derek J sold $114,573 worth of shares (5,644 units at $20.30), decreasing direct ownership by 2% to 77,099 units (SEC Form 4)
4 - CASTLE BIOSCIENCES INC (0001447362) (Issuer)
Director Cotton Rodney converted options into 5,329 shares (SEC Form 4)
4 - CASTLE BIOSCIENCES INC (0001447362) (Issuer)
Amendment: SEC Form 4 filed by Director Cotton Rodney
4/A - CASTLE BIOSCIENCES INC (0001447362) (Issuer)
Amendment: SEC Form 4 filed by Director Cotton Rodney
4/A - CASTLE BIOSCIENCES INC (0001447362) (Issuer)
Pres. & Chief Exec. Officer Maetzold Derek J sold $585,673 worth of shares (29,177 units at $20.07), decreasing direct ownership by 24% to 78,335 units (SEC Form 4)
4 - CASTLE BIOSCIENCES INC (0001447362) (Issuer)
Pres. & Chief Exec. Officer Maetzold Derek J converted options into 31,109 shares, covered exercise/tax liability with 7,576 shares and sold $118,619 worth of shares (5,687 units at $20.86), increasing direct ownership by 28% to 103,104 units (SEC Form 4)
4 - CASTLE BIOSCIENCES INC (0001447362) (Issuer)
Chief Commercial Officer Juvenal Tobin W converted options into 13,811 shares and covered exercise/tax liability with 5,573 shares, increasing direct ownership by 12% to 78,181 units (SEC Form 4)
4 - CASTLE BIOSCIENCES INC (0001447362) (Issuer)
Chief Operating Officer Oelschlager Kristen M converted options into 13,811 shares and covered exercise/tax liability with 3,640 shares, increasing direct ownership by 7% to 163,964 units (SEC Form 4)
4 - CASTLE BIOSCIENCES INC (0001447362) (Issuer)
Chief Financial Officer Stokes Frank converted options into 12,186 shares and covered exercise/tax liability with 5,448 shares, increasing direct ownership by 18% to 43,328 units (SEC Form 4)
4 - CASTLE BIOSCIENCES INC (0001447362) (Issuer)
Chief Financial Officer Stokes Frank sold $214,828 worth of shares (8,046 units at $26.70), decreasing direct ownership by 19% to 35,319 units (SEC Form 4)
4 - CASTLE BIOSCIENCES INC (0001447362) (Issuer)
Castle Biosciences Inc. SEC Filings
SEC Form PRE 14A filed by Castle Biosciences Inc.
PRE 14A - CASTLE BIOSCIENCES INC (0001447362) (Filer)
SEC Form 144 filed by Castle Biosciences Inc.
144 - CASTLE BIOSCIENCES INC (0001447362) (Subject)
SEC Form 144 filed by Castle Biosciences Inc.
144 - CASTLE BIOSCIENCES INC (0001447362) (Subject)
SEC Form S-8 filed by Castle Biosciences Inc.
S-8 - CASTLE BIOSCIENCES INC (0001447362) (Filer)
SEC Form 10-K filed by Castle Biosciences Inc.
10-K - CASTLE BIOSCIENCES INC (0001447362) (Filer)
Castle Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
8-K - CASTLE BIOSCIENCES INC (0001447362) (Filer)
SEC Form 144 filed by Castle Biosciences Inc.
144 - CASTLE BIOSCIENCES INC (0001447362) (Subject)
Amendment: SEC Form SCHEDULE 13G/A filed by Castle Biosciences Inc.
SCHEDULE 13G/A - CASTLE BIOSCIENCES INC (0001447362) (Subject)
Castle Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
8-K - CASTLE BIOSCIENCES INC (0001447362) (Filer)
SEC Form 144 filed by Castle Biosciences Inc.
144 - CASTLE BIOSCIENCES INC (0001447362) (Subject)
Castle Biosciences Inc. Leadership Updates
Live Leadership Updates
Castle Biosciences Kicks off Skin Cancer Awareness Month with a Ribbon Cutting to Celebrate the City of Friendswood's Designation as a Sun Safe Leadership Model City by IMPACT Melanoma
The Company is proud to collaborate on a number of additional initiatives during the month of May Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced its support of key skin cancer advocacy events and initiatives throughout May in honor of Skin Cancer Awareness Month. The first such event is a ribbon cutting to honor the City of Friendswood's designation as a Sun Safe Leadership Model City — the first in Texas — by IMPACT Melanoma. The ribbon cutting will take place at Stevenson Park in Friendswood, Texas, on Friday, May 3, 2024, at 10:00 a.m. Central time. "Skin cancer is the most common cancer in the Unit
Persephone Biosciences Appoints Daniel Bradbury as Chair of the Board of Directors
-Mr. Bradbury has over 35 years of experience leading fast-growing life sciences companies- Persephone Biosciences Inc., a biotechnology company reimagining patient health through the development of microbiome-based medicines, today announced that it has appointed Daniel Bradbury as Chair of the Board of Directors. "We are delighted to welcome Dan to our Board. His appointment reflects the recent progress we have made with our MyBabyBiome™ study of infant gut health, and our near-term plans to commercialize our first product based on the findings. Additionally, Persephone has a further two clinical studies underway, namely our ARGONAUT study of gut microbiome-linked immune modulation in
AltheaDx, Inc. appoints industry veteran Derek Maetzold to its Board of Directors
SAN DIEGO, May 26, 2021 /PRNewswire/ -- AltheaDx, a commercial stage, precision medicine company with the world's leading pharmacogenomics test for anxiety and depression announced today that it has appointed Derek Maetzold to its Board of Directors. Mr. Maetzold is AltheaDx's fourth Director and brings not only strong knowledge of the diagnostics industry, but also operations and management experience. Mr. Maetzold is the Founder and CEO of publicly listed Castle Biosciences (NASDAQ:CSTL). Previously he held leadership roles at Encysive Pharmaceuticals, Amylin Pharmaceuticals, Sandoz and Schering-Plough. Castle Biosciences has gained Medicare reimbursement coverage and has had a successful
Castle Biosciences Inc. Financials
Live finance-specific insights
Castle Biosciences Reports Fourth Quarter and Full-Year 2024 Results
Full-year 2024 revenue of $332 million, an increase of 51% compared to 2023 and above previously reported guidance Delivered 96,071 total test reports in 2024, an increase of 36% compared to 2023 Year-end 2024 cash, cash equivalents and marketable investment securities of $293 million, a $50 million increase compared to 2023 Anticipate generating between $280-295 million in total revenue in 2025 Conference call and webcast today at 4:30 p.m. ET Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced its financial results for the fourth quarter and year ended December 31, 2024. "Castle delivered an outst
Castle Biosciences to Release Fourth Quarter and Full-Year 2024 Financial Results and Host Conference Call on Thursday, Feb. 27, 2025
Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced that it will release its financial results for the fourth quarter and year ended Dec. 31, 2024, after the close of market on Thursday, Feb. 27, 2025. Company management will host a conference call and webcast to discuss its financial results at 4:30 p.m. Eastern time on the same day. Conference Call and Webcast Details A live webcast of the conference call can be accessed here: https://events.q4inc.com/attendee/686536610, or via the webcast link on the Investor Relations page of the Company's website: https://ir.castlebiosciences.com/overview/default.asp
Castle Biosciences Reports Third Quarter 2024 Results
Q3 2024 revenue increased 39% over Q3 2023 to $86 million Q3 2024 total test reports increased 41% over Q3 2023 Raising full-year 2024 revenue guidance to $320-330 million from $275-300 million Conference call and webcast today at 4:30 p.m. ET Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced its financial results for the third quarter and nine months ended September 30, 2024. "We are thrilled with our third quarter performance, which reflects the continued success of our growth initiatives and the dedication of our team," said Derek Maetzold, president and chief executive officer of Castle Biosciences.
Castle Biosciences to Release Third Quarter 2024 Financial Results and Host Conference Call on Monday, Nov. 4, 2024
Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced that it will release its financial results for the third quarter and nine months ended Sept. 30, 2024, after the close of market on Monday, Nov. 4, 2024. Company management will host a conference call and webcast to discuss its financial results at 4:30 p.m. Eastern time on the same day. Conference Call and Webcast Details A live webcast of the conference call can be accessed here: https://events.q4inc.com/attendee/435529710, or via the webcast link on the Investor Relations page of the Company's website: https://ir.castlebiosciences.com/overview/default.as
Castle Biosciences Reports Second Quarter 2024 Results
Q2 2024 revenue increased 74% over Q2 2023 to $87 million Q2 2024 total test reports increased 49% over Q2 2023 Raising full-year 2024 revenue guidance to $275-300 million from $255-265 million Conference call and webcast today at 4:30 p.m. ET Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced its financial results for the second quarter and six months ended June 30, 2024. "We achieved another quarter of exceptional performance, thanks to the hard work of our talented team and strength of our innovative test portfolio," said Derek Maetzold, president and chief executive officer of Castle Biosciences.
Castle Biosciences to Release Second Quarter 2024 Financial Results and Host Conference Call on Monday, Aug. 5, 2024
Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced that it will release its financial results for the second quarter and six months ended June 30, 2024, after the close of market on Monday, Aug. 5, 2024. Company management will host a conference call and webcast to discuss its financial results at 4:30 p.m. Eastern time on the same day. Conference Call and Webcast Details A live webcast of the conference call can be accessed here: https://events.q4inc.com/attendee/952012940, or via the webcast link on the Investor Relations page of the Company's website: https://ir.castlebiosciences.com/overview/default.
Castle Biosciences Honored with Top Workplaces Awards
Castle earns recognition as an Arizona Top Workplace, a national Healthcare Industry Top Workplace and receives five Top Workplaces Culture Excellence Awards Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced that it has earned multiple awards through the 2024 Top Workplaces program, including: a third consecutive Arizona Top Workplaces award from AZ Central, the digital home of The Arizona Republic newspaper; a second consecutive national Healthcare Industry Top Workplaces award; and five Top Workplaces Culture Excellence Awards for Innovation, Work-Life Flexibility, Compensation & Benefits, Leadership and
Castle Biosciences Reports First Quarter 2024 Results
Q1 2024 revenue increased 74% over Q1 2023 to $73 million Q1 2024 total test reports increased 40% over Q1 2023 Raising full-year 2024 revenue guidance to $255-265 million from $235-240 million Conference call and webcast today at 4:30 p.m. ET Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced its financial results for the first quarter ended March 31, 2024. "The first quarter marked an excellent start to the year with strong execution across the company, resulting in outstanding revenue and volume growth across our therapeutic areas," said Derek Maetzold, president and chief executive officer of Cas
Castle Biosciences to Release First Quarter 2024 Financial Results and Host Conference Call on Thursday, May 2, 2024
Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced that it will release its financial results for the first quarter ended March 31, 2024, after the close of market on Thursday, May 2, 2024. Company management will host a conference call and webcast to discuss its financial results at 4:30 p.m. Eastern time on the same day. Conference Call and Webcast Details A live webcast of the conference call can be accessed here: https://events.q4inc.com/attendee/562496463, or via the webcast link on the Investor Relations page of the Company's website: https://ir.castlebiosciences.com/overview/default.aspx. Please a
Castle Biosciences Reports Fourth Quarter and Full-Year 2023 Results
Full-year 2023 revenue of $220 million, an increase of 60% compared to 2022 and above previously reported guidance Delivered 70,429 total test reports in 2023, an increase of 59% compared to 2022 Year-end 2023 cash, cash equivalents and marketable investment securities of $243 million Two critical peer-reviewed publications in 2023 demonstrating an association with DecisionDx®-Melanoma testing and improved patient outcomes Conference call and webcast today at 4:30 p.m. ET Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced its financial results for the fourth quarter and year ended Dec. 31, 2023. "2
Castle Biosciences Inc. Large Ownership Changes
This live feed shows all institutional transactions in real time.
Amendment: SEC Form SC 13G/A filed by Castle Biosciences Inc.
SC 13G/A - CASTLE BIOSCIENCES INC (0001447362) (Subject)
Amendment: SEC Form SC 13G/A filed by Castle Biosciences Inc.
SC 13G/A - CASTLE BIOSCIENCES INC (0001447362) (Subject)
Amendment: SEC Form SC 13G/A filed by Castle Biosciences Inc.
SC 13G/A - CASTLE BIOSCIENCES INC (0001447362) (Subject)
SEC Form SC 13G filed by Castle Biosciences Inc.
SC 13G - CASTLE BIOSCIENCES INC (0001447362) (Subject)
SEC Form SC 13G filed by Castle Biosciences Inc.
SC 13G - CASTLE BIOSCIENCES INC (0001447362) (Subject)
SEC Form SC 13G/A filed by Castle Biosciences Inc. (Amendment)
SC 13G/A - CASTLE BIOSCIENCES INC (0001447362) (Subject)
SEC Form SC 13G/A filed by Castle Biosciences Inc. (Amendment)
SC 13G/A - CASTLE BIOSCIENCES INC (0001447362) (Subject)
SEC Form SC 13G/A filed by Castle Biosciences Inc. (Amendment)
SC 13G/A - CASTLE BIOSCIENCES INC (0001447362) (Subject)
SEC Form SC 13G filed by Castle Biosciences Inc.
SC 13G - CASTLE BIOSCIENCES INC (0001447362) (Subject)
SEC Form SC 13G/A filed by Castle Biosciences Inc. (Amendment)
SC 13G/A - CASTLE BIOSCIENCES INC (0001447362) (Subject)